Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 117, Issue 23, Pages 13023-13032Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2002567117
Keywords
HIF2 alpha; USP37; deubiquitination; ccRCC
Categories
Funding
- National Cancer Institute [R01CA211732, R21CA223675]
- Cancer Prevention and Research Institute of Texas (CPRIT) [RR190058]
- Eunice Kennedy Shriver National Institute of Child Health and Human Development [U54HD079124]
- National Institute of Neurological Disorders and Stroke (NINDS) [P30NS045892]
Ask authors/readers for more resources
Clear cell renal cell carcinoma (ccRCC) is characterized by loss of tumor suppressor Von Hippel Lindau (VHL) function, which leads to accumulation of hypoxia inducible factor a (including HIF1 alpha and HIF2 alpha). HIF2 alpha was previously reported to be one of the major oncogenic drivers in ccRCC, however, its therapeutic targets remain challenging. Here we performed a deubiquitinase (DUB) complementary DNA (cDNA) library binding screen and discovered that ubiquitin-specific peptidase 37 (USP37) is a DUB that binds HIF2 alpha and promotes HIF2 alpha deubiquitination. As a result, USP37 promotes HIF2 alpha protein stability in an enzymatically dependent manner, and depletion of USP37 leads to HIF2 alpha down-regulation in ccRCC. Functionally, USP37 depletion causes decreased cell proliferation measured by MTS, two-dimensional (2D) colony formation as well as three-dimensional (3D) anchorage- independent growth. USP37 is also essential for maintaining kidney tumorigenesis in an orthotopic xenograft model and its depletion leads to both decreased primary kidney tumorigenesis and spontaneous lung metastasis. Our results suggest that USP37 is a potential therapeutic target in ccRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available